Vitamin C Stacking

Facebook
Twitter
LinkedIn
Email
WhatsApp

Vitamin C Stacking. What is it? Is stacking the next-in-line biohacking trends? Absolutely not. Stacking is the principle of adding different therapies together in combination or sequence with high-dose vitamin C to augment the physiologic impact. The goal is to synergize and maximize the intended effects of therapy in genomics, epigenomics, transcriptomics, proteomics, metabolomics, and immunomodulomics. Yes, those are actual words. Moreover, they are the exciting fields of “omic” research that are bringing the future of precision medicine to today.

Stacking therapies integrate perfectly within the context of the integrative medicine movement. The historical and contextual meaning of the words integrative or integration have both Latin and French origins. The more recent historical contextual significance is French and means the “act of bringing together the parts of a whole.” In a more ancient context, the Latin word integrationem means “renewal, restoration, make whole, renew, and begin again.” Both definitions ascribe more to the holistic paradigm of the holistic, integrative medicine movement. In contrast, a compartmentalized approach, often in deference to the whole, is the dominant view within conventional medicine.

Many holistic and integrative practitioners augment high-dose intravenous vitamin C through the principle of stacking. Let me approach this from an evidence-based perspective of stacking therapies more in treating cancer. Common evidence-based cancer stacking therapies with vitamin C in the treatment of cancer include:

  • High-dose IV vitamin C + water Fasting
  • High-dose IV vitamin C + Melatonin
  • High-dose IV vitamin C + Alpha Lipoic Acid
  • High-dose IV vitamin C + Hyperthermia
  • High-dose IV vitamin C + Hyperbaric Oxygen Therapy
  • High-dose IV vitamin C + Artemisinin/Artesunate
  • High-dose IV vitamin C + vitamin K3
  • High-dose IV vitamin C + Dichloroacetate (DCA)
  • High-dose IV vitamin C + Mistletoe

Though the research here is not voluminous, the supporting evidence exists in combination studies or through common therapeutic effects.

Not all stacking is beneficial, especially concerning patients with cancer. There is evidence to avoid specific vitamin C stacking therapy combinations in cancer. One of the significant pro-oxidant effects of vitamin C is the depletion of the reduced form of glutathione, which creates a detoxification crisis. As a result, the stacking of N-acetyl-cysteine or glutathione with high-dose IV vitamin C should be avoided. In addition, another major pro-oxidant effect of vitamin C in cancer is the depletion of NADH and NADPH, creating an energy crisis. As a result, the stack of NAD+ with high-dose vitamin C should be avoided. It is essential to realize that these caveats are carved out in cancer only.

Beyond a purely holistic stacking of therapies, the stacking principle crosses the cancer therapy aisle to include conventional cancer therapies. Evidence-based support for stacking High-dose vitamin C with conventional cancer therapies includes:

  • High-dose IV vitamin C + Chemotherapy
  • High-dose IV vitamin C + Radiation
  • High-dose IV vitamin C + Surgery
  • High-dose IV vitamin C + Conventional Immunotherapy
  • High-dose IV vitamin C + Conventional Targeted therapies
  • High-dose IV vitamin C + Conventional Hormone therapies

Vitamin C is the flagship therapy of Integrative medicine. Beyond a flagship therapy, high-dose vitamin C and the principle of vitamin C stacking are the bridge that crosses the abyss between holistic, integrative medicine and conventional medicine.

References:

Di Tano M, Raucci F, Vernieri C, Caffa I, Buono R, Fanti M, Brandhorst S, Curigliano G, Nencioni A, de Braud F, Longo VD. Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. Nat Commun. 2020 May 11;11(1):2332. doi: 10.1038/s41467-020-16243-3.

Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI. Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities. Molecules. 2021 Apr 25;26(9):2506. doi: 10.3390/molecules26092506.

Mussa A, Mohd Idris RA, Ahmed N, Ahmad S, Murtadha AH, Tengku Din TADAA, Yean CY, Wan Abdul Rahman WF, Mat Lazim N, Uskoković V, Hajissa K, Mokhtar NF, Mohamud R, Hassan R. High-Dose Vitamin C for Cancer Therapy. Pharmaceuticals (Basel). 2022 Jun 3;15(6):711. doi: 10.3390/ph15060711

Novotny L, Rauko P, Cojocel C. alpha-Lipoic acid: the potential for use in cancer therapy. Neoplasma. 2008;55(2):81-6. PMID: 18237244.

Ou J, Zhu X, Lu Y, Zhao C, Zhang H, Wang X, Gui X, Wang J, Zhang X, Zhang T, Pang CLK. The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer. Eur J Pharm Sci. 2017 Nov 15;109:412-418. doi: 10.1016/j.ejps.2017.08.011.

DeBlasi, J.M., Ward, N.P., Poff, A.M., Koutnik, A.P., Rogers, C.Q. and D’Agostino, D.P. (2017), Anti-Cancer Effects of Ascorbic Acid and Hyperbaric Oxygen Therapy in vitro. The FASEB Journal, 31: 879.4-879.4. https://doi.org/10.1096/fasebj.31.1_supplement.879.4

Yang X, Zheng Y, Liu L, Huang J, Wang F, Zhang J. Progress on the study of the anticancer effects of artesunate. Oncol Lett. 2021 Nov;22(5):750. doi: 10.3892/ol.2021.13011.

Bonilla-Porras AR, Jimenez-Del-Rio M, Velez-Pardo C. Vitamin K3 and vitamin C alone or in combination induced apoptosis in leukemia cells by a similar oxidative stress signalling mechanism. Cancer Cell Int. 2011 Jun 10;11:19. doi: 10.1186/1475-2867-11-19.

Tataranni T, Piccoli C. Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications. Oxid Med Cell Longev. 2019 Nov 14;2019:8201079. doi: 10.1155/2019/8201079.

Mohammed E. Improved liver function after high dose intravenous vitamin C and Helxior SC injections in a patient with hepatocellular carcinoma progressed after chemotherapy and radiation. J Cancer Prev Curr Res. 2018;9(4):201-203. DOI: 10.15406/jcpcr.2018.09.00350

Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., Chen, Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci. Transl. Med.2014;6,222ra218.

Cieslak JA, Sibenaller ZA, Walsh SA, et al. Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy. Radiat Res. 2016;185(1):31–38. doi:10.1667/RR14203.1

Mehdi Z, Petronek MS, Stolwijk JM, Mapuskar KA, Kalen AL, Buettner GR, Cullen JJ, Spitz DR, Buatti JM, Allen BG. Utilization of Pharmacological Ascorbate to Enhance Hydrogen Peroxide-Mediated Radiosensitivity in Cancer Therapy. Int J Mol Sci. 2021 Oct 8;22(19):10880. doi: 10.3390/ijms221910880.

Magrì A, Germano G, Lorenzato A, Lamba S, Chilà R, Montone M, Amodio V, Ceruti T, Sassi F, Arena S, Abrignani S, D’Incalci M, Zucchetti M, Nicolantonio FD, Bardelli A. High-dose vitamin C enhances cancer immunotherapy. Sci. Transl. Med. 2020 Feb 26;12(532). pii: eaay8707. doi: 10.1126/scitranslmed.aay8707.

Lee SJ, Jeong JH, Lee IH, Lee J, Jung JH, Park HY, Lee DH, Chae YS. Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells. Anticancer Res. 2019 Feb;39(2):751-758. doi: 10.21873/anticanres.13172.

Böttger F, Vallés-Martí A, Cahn L, Jimenez CR. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. J Exp Clin Cancer Res. 2021 Oct 30;40(1):343. doi: 10.1186/s13046-021-02134-y.

Dachs GU, Gandhi J, Wohlrab C, Carr AC, Morrin HR, Pullar JM, Bayer SB, Eglinton TW, Robinson BA, Vissers MCM. Vitamin C Administration by Intravenous Infusion Increases Tumor Ascorbate Content in Patients With Colon Cancer: A Clinical Intervention Study. Front Oncol. 2021 Jan 11;10:600715. doi: 10.3389/fonc.2020.600715.

Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. Clin Transl Med. 2020 Jan;10(1):199-223. doi: 10.1002/ctm2.24.

Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015 Sep;125(9):3347-55. doi: 10.1172/JCI80007.